Research graph
References from Deficiency of the Lipoprotein Lipase Pathway Modifies the Phenotypic Expression of Genetically Determined Lipoprotein(a). Local targets link to admitted publications; unresolved targets remain external evidence.
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
10.1016/j.jacc.2017.11.014 · 2018 · External reference
Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma
10.1172/jci113093 · 1987 · External reference
Structure, function, and genetics of lipoprotein (a)
10.1194/jlr.r067314 · 2016 · External reference
Lipoprotein(a) metabolism: potential sites for therapeutic targets
10.1016/j.metabol.2012.07.024 · 2013 · External reference
Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population
10.1016/0021-9150(93)90117-d · 1993 · External reference
Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia
10.1016/0021-9150(94)90109-0 · 1994 · External reference
Effect of hypertriglyceridaemia on lipoprotein (a) serum concentrations
10.1111/j.1365-2362.1995.tb01707.x · 1995 · External reference
10.1016/j.jacc.2009.02.041
10.1016/j.jacc.2009.02.041 · 2009 · External reference
Comparison of Patients With Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia Syndrome
10.1210/clinem/dgae613 · 2025 · External reference
Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a)
10.1172/jci116074 · 1992 · External reference
Oxidized phospholipids in cardiovascular disease
10.1038/s41569-023-00937-4 · 2024 · External reference
Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study
10.1161/circulationaha.108.836940 · 2009 · External reference
Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia
10.1194/jlr.p027235 · 2012 · External reference
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1016/j.jacc.2025.11.016 · 2026 · External reference
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
10.1056/nejmoa2400201 · 2024 · External reference
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
10.1056/nejmoa2507227 · 2025 · External reference
Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study
10.1161/circulationaha.126.080012 · 2026 · External reference
Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a)
10.1016/j.jlr.2022.100239 · 2022 · External reference
Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature
10.1093/clinchem/42.3.436 · 1996 · External reference
Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)
10.1093/clinchem/41.2.246 · 1995 · External reference
Lp(a), oxidized phospholipids and oxidation-specific epitopes are increased in subjects with keloid formation
10.1186/s12944-022-01720-z · 2022 · External reference
Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
10.1016/j.jacc.2023.02.050 · 2023 · External reference
A Novel Triglyceride- and Cholesterol-Enriched Lipoprotein(a) Phenotype in Moderate Hypertriglyceridemia: Reversal by ApoC-III Inhibition
10.1016/j.jacbts.2026.101699 · 2026 · External reference
A novel immune-isolation method for direct quantification of triglycerides associated with lipoprotein(a)
10.1016/j.jlr.2026.100996 · 2026 · External reference
Lipoprotein(a) carries triglyceride species associated with incident cardiovascular disease
10.1016/j.atherosclerosis.2026.121866 · 2026 · External reference
Reduced lipoprotein (a) in patients with severe hypertriglyceridaemia
10.1177/03000605241289294 · 2024 · External reference
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
10.1056/nejmoa1905239 · 2020 · External reference
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
10.1056/nejmoa1715944 · 2019 · External reference
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
10.1056/nejmoa2409368 · 2025 · External reference
Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association
10.1016/j.jacl.2026.01.011 · 2026 · External reference
Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology
10.1016/j.jacl.2025.03.012 · 2025 · External reference
Prevalence of familial chylomicronemia syndrome in a quaternary care center
10.1177/2047487319888054 · 2020 · External reference
